The reported response rate in this subpopulation is consistently very low.11,12 Intriguingly, in the present study, c-Met overexpression (defined as ≥50% of tumor cells with strong 3+ staining intensity) coupled with SYK overexpression identified a subpopulation of NSCLC patients with a high response rate (73.3%) to c-Metis. This evidence concerns the gene MET and non-small cell lung carcinoma.